Clinical Trial

The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM

Study acronym: pAVM-rFA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have focused specifically on flow-related aneurysms alone. In many instances, the source of rupture is also unclear. Meta-analysis from 2016 suggested that 49.2% of hemorrhages were secondary to aneurysm rupture, 45% from AVM rupture, and 5.7% were undetermined.In a study of 302 patients, of which 52.6% had a hemorrhagic presentation, demonstrated a significant increase in rate of hemorrhage in those with flow-related aneurysms. Thus, it is necessary to figure out risk factors related to ruptured flow-related aneurysms in pAVM.
Trial Details
NCT Number NCT07050381
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Arteriovenous Malformation of Central Nervous System, Aneurysm, Ruptured, Aneurysmatic Subarachnoid Haemorrhage, Aneurysm Cerebral
Enrollment 200 participants
Start Date 2025-06-13
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-03